In the subgroup analysis of left-sided CRC with RAS/BRAF WT, there were no significant differences among the double-drug therapy with bevacizumab, the double-drug therapy with cetuximab/panitumumab, and the triple-drug therapy with bevacizumab. The gene discussed is BRAF; the disease is colorectal carcinoma.